Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Sees Large Growth in Short Interest

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNSGet Rating) was the target of a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 1,090,000 shares, a growth of 17.6% from the August 15th total of 927,200 shares. Based on an average trading volume of 293,600 shares, the days-to-cover ratio is currently 3.7 days. Currently, 3.4% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on MRNS. StockNews.com downgraded Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 12th. JMP Securities reiterated a “buy” rating and issued a $22.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, June 9th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $32.17.

Marinus Pharmaceuticals Trading Up 1.8 %

NASDAQ:MRNS opened at $6.80 on Monday. Marinus Pharmaceuticals has a 12-month low of $3.97 and a 12-month high of $13.15. The firm has a market capitalization of $252.95 million, a P/E ratio of -2.36 and a beta of 1.36. The company has a debt-to-equity ratio of 92.57, a current ratio of 4.37 and a quick ratio of 4.37. The business has a 50 day simple moving average of $6.15 and a 200 day simple moving average of $6.46.

Marinus Pharmaceuticals (NASDAQ:MRNSGet Rating) last announced its quarterly earnings results on Thursday, August 11th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.13). Marinus Pharmaceuticals had a negative return on equity of 266.12% and a negative net margin of 386.11%. The business had revenue of $1.79 million for the quarter, compared to analyst estimates of $2.25 million. Equities research analysts predict that Marinus Pharmaceuticals will post -1.9 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. boosted its position in Marinus Pharmaceuticals by 2.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,047 shares of the biopharmaceutical company’s stock worth $889,000 after acquiring an additional 2,281 shares during the period. Quantbot Technologies LP acquired a new position in Marinus Pharmaceuticals during the 1st quarter worth $40,000. Price T Rowe Associates Inc. MD boosted its position in Marinus Pharmaceuticals by 39.5% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 15,600 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 4,417 shares during the period. Virtus ETF Advisers LLC boosted its position in Marinus Pharmaceuticals by 40.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 15,932 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 4,597 shares during the period. Finally, Sofinnova Investments Inc. boosted its position in Marinus Pharmaceuticals by 2.8% during the 4th quarter. Sofinnova Investments Inc. now owns 171,338 shares of the biopharmaceutical company’s stock worth $2,035,000 after acquiring an additional 4,627 shares during the period. Institutional investors and hedge funds own 77.43% of the company’s stock.

About Marinus Pharmaceuticals

(Get Rating)

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Featured Articles

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.